logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11186824 B1

PDFFull Text
Date of Patent:
Nov. 30, 2021

Filed:

Mar. 11, 2016

Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients

Applicant:

Cellectis, Paris, FR;

Inventors:

Philippe Duchateau, Draveil, FR;

Jean-Pierre Cabaniols, Saint Lau la Foret, FR;

Julien Valton, New York, NY (US);

Laurent Poirot, Paris, FR;

Assignee:

CELLECTIS, Paris, FR;

Attorney:

Arrigo, Lee, Guttman & Mouta-Bellum LLP

Primary Examiner:

Ileana Popa

Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 48/00 (2006.01); C12N 5/0783 (2010.01); C12N 5/00 (2006.01); C07K 14/005 (2006.01); C07K 14/705 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0638 (2013.01); A61K 35/17 (2013.01); C07K 14/005 (2013.01); C07K 14/70503 (2013.01); C07K 14/70532 (2013.01); C07K 14/70539 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 5/0006 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); A01K 2207/12 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2319/00 (2013.01); C12N 2310/20 (2017.05); C12N 2501/48 (2013.01); C12N 2501/51 (2013.01); C12N 2501/599 (2013.01); C12N 2510/00 (2013.01); C12N 2710/16122 (2013.01); C12N 2710/16133 (2013.01); C12N 2710/16171 (2013.01); C12N 2800/80 (2013.01);
Abstract

The present invention relates to methods for developing engineered immune cells such as T-cells for immunotherapy that have a higher potential of persistence and/or engraftment in host organism. IN particular, this method involves an inactivation of at least one gene involved in self/non self recognition, combined with a step of contact with at least one non-endogenous immunosuppressive polypeptide. The invention allows the possibility for a standard and affordable adoptive immunotherapy, whereby the risk of GvH is reduced.

Find Patent Forward Citations

Duchateau, Philippe. (2021). Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients (U.S. Patent No. 11186824). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11186824

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…